Skip to search formSkip to main contentSkip to account menu

ertugliflozin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
MON-LB124 Euglycemic Diabetic Ketoacidosis on Initiation of Ertugliflozin in a Patient With Type 2 Diabetes Mellitus Precipitated by a Ketogenic Diet
Abstract Background: Diabetic ketoacidosis (DKA) is defined by metabolic acidosis, ketosis and hyperglycemia. It is considered to… 
2019
2019
Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
A fixed‐dose combination (FDC) tablet of ertugliflozin, a selective inhibitor of sodium‐glucose cotransporter 2, and sitagliptin… 
2018
2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
Ertugliflozin, a sodium‐glucose cotransporter 2 inhibitor for the treatment of adults with type 2 diabetes mellitus, is expected… 
Review
2018
Review
2018
Ertugliflozin as a monotherapy for the treatment of type 2 diabetes
ABSTRACT Introduction: Sodium-dependent glucose transporter 2 (SGLT2) inhibitors are novel, potent oral anti-diabetic agents in a… 
Review
2018
Review
2018
Ertugliflozin for treatment of patients with Type 2 diabetes mellitus
ABSTRACT Introduction: Type 2 diabetes mellitus (T2DM) is a growing and serious global health problem. Inhibition of the sodium… 
2018
2018
New Drug Treats Rare, Debilitating Neurotrophic Keratitis.
  • R. Voelker
  • Journal of the American Medical Association (JAMA…
  • 2018
  • Corpus ID: 205096395
2018
2018
Ertugliflozin (Steglatro): A New Option for SGLT2 Inhibition.
Steglatro (ertugliflozin) for glycemic control in adults with type-2 diabetes mellitus. 
Review
2018
Review
2018
Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
Sodium glucose-cotransporter-2 inhibitors (SGLT-2i) act independently of pancreatic β-cell function and inhibit glucose uptake in… 
2018
2018
Ertugliflozin for Type 2 Diabetes
  • Journal of the American Medical Association (JAMA…
  • 2018
  • Corpus ID: 49311237
2017
2017
Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)